Article Text

Download PDFPDF
IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5
  1. Nabil Antaki1,
  2. Stéphanie Bibert2,
  3. Kamel Kebbewar3,
  4. Fouad Asaad4,
  5. Osama Baroudi5,
  6. Sawsan Alideeb5,
  7. Milad Hadad6,
  8. Dirar Abboud1,
  9. Houda Sabah7,
  10. Pierre-Yves Bochud2,
  11. Francesco Negro8
  1. 1Department of Gastroenterology, Saint Louis Hospital, Ismailiye, Aleppo, Syria
  2. 2Service of Infectious Diseases, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
  3. 3Laboratory Medicine, Saint Louis Hospital, Ismailiye, Aleppo, Syria
  4. 4Department of Internal Medicine, Squelbiye National Hospital, Squelbiye, Syria
  5. 5Department of Gastroenterology, Damascus Hospital, Damascus, Syria
  6. 6Department of Gastroenterology, Ibn Nafis Hospital, Damascus, Syria
  7. 7Department of Laboratory Medicine, Damascus Hospital, Damascus, Syria
  8. 8Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland
  1. Correspondence to Professor Francesco Negro, Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, 4 rue Gabrielle-Perret-Gentil, CH-1211 Geneva 14, Switzerland; francesco.negro{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the paper by Hayes et al 1 on the impact of genetic polymorphisms near IL28B in predicting treatment response in chronic hepatitis C patients infected with hepatitis C virus genotype 1 (HCV-1). These results confirm the large, existing evidence in support of single nucleotide polymorphisms (SNPs) near IL28B being the most powerful predictors of virological response in patients infected with all major HCV genotypes, that is, 1–4.2 No data is available for HCV-5, a rare genotype neglected in clinical trials.3 We report IL28B SNP frequency and its impact on treatment outcome in 49 patients of homogeneous Caucasian ancestry, all from Syria, infected with HCV-5. Treatment included 180 μg …

View Full Text


  • Linked article 223495.

  • P-YB and FN contributed equally to this work.

  • Funding PYB is supported by the Swiss National Science Foundation (32003B-127613), the Leenaards Foundation, and the Santos-Suarez Foundation.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by ethics committee of Saint Louis Hospital, Aleppo (Ref. No. 2011-2).

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles